BACKGROUND: To evaluate the effectiveness of low-dose radiation therapy (LDRT) and FOLFIRI-bevacizumab (FOLFIRI-B) combination in metastatic colorectal cancer. METHODS: The primary objective of the study is to raise the clinical complete response (CR) rate from 5% to 25%. Secondary objectives include toxicity and progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT (20 cGy/6-hour interval) on the first and second days of each cycle. RESULTS: CR and toxicity of 10 patients are reported. Considering irradiated sites, 10/10 patients had clinical partial response (PR) (7/10) or CR (3/10). Three clinical PR patients subsequently underwent surgery and reported a pathological CR in the irradiated sites. Grade 3-4 toxicities rate was 30%. With a median follow-up of 29 months (range: 12-49 months), 2/10 progression of disease in irradiated sites and 3/5 in non-irradiated sites were observed. CONCLUSIONS: The very high response rate requires urgent verification in a larger patient series.
BACKGROUND: To evaluate the effectiveness of low-dose radiation therapy (LDRT) and FOLFIRI-bevacizumab (FOLFIRI-B) combination in metastatic colorectal cancer. METHODS: The primary objective of the study is to raise the clinical complete response (CR) rate from 5% to 25%. Secondary objectives include toxicity and progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT (20 cGy/6-hour interval) on the first and second days of each cycle. RESULTS:CR and toxicity of 10 patients are reported. Considering irradiated sites, 10/10 patients had clinical partial response (PR) (7/10) or CR (3/10). Three clinical PR patients subsequently underwent surgery and reported a pathological CR in the irradiated sites. Grade 3-4 toxicities rate was 30%. With a median follow-up of 29 months (range: 12-49 months), 2/10 progression of disease in irradiated sites and 3/5 in non-irradiated sites were observed. CONCLUSIONS: The very high response rate requires urgent verification in a larger patient series.
Entities:
Keywords:
Bevacizumab,; Chemo-sensitization,; Low-dose radiotherapy,; Metastatic colorectal cancer
Authors: Douglas E Ney; Julie A Carlson; Denise M Damek; Laurie E Gaspar; Brian D Kavanagh; B K Kleinschmidt-DeMasters; Allen E Waziri; Kevin O Lillehei; Krishna Reddy; Changhu Chen Journal: J Neurooncol Date: 2014-12-19 Impact factor: 4.130
Authors: Mohammad Javed Ansari; Dmitry Bokov; Alexander Markov; Abduladheem Turki Jalil; Mohammed Nader Shalaby; Wanich Suksatan; Supat Chupradit; Hasan S Al-Ghamdi; Navid Shomali; Amir Zamani; Ali Mohammadi; Mehdi Dadashpour Journal: Cell Commun Signal Date: 2022-04-07 Impact factor: 5.712
Authors: Kimberly M Arnold; Nicole J Flynn; Adam Raben; Lindsay Romak; Yan Yu; Adam P Dicker; Firas Mourtada; Jennifer Sims-Mourtada Journal: Cancer Growth Metastasis Date: 2018-03-09